These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 23568259)
1. Gene silencing via RNAi and siRNA quantification in tumor tissue using MEND, a liposomal siRNA delivery system. Sakurai Y; Hatakeyama H; Sato Y; Hyodo M; Akita H; Harashima H Mol Ther; 2013 Jun; 21(6):1195-203. PubMed ID: 23568259 [TBL] [Abstract][Full Text] [Related]
2. RNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system. Sakurai Y; Hatakeyama H; Sato Y; Hyodo M; Akita H; Ohga N; Hida K; Harashima H J Control Release; 2014 Jan; 173():110-8. PubMed ID: 24120854 [TBL] [Abstract][Full Text] [Related]
3. A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo. Sato Y; Hatakeyama H; Sakurai Y; Hyodo M; Akita H; Harashima H J Control Release; 2012 Nov; 163(3):267-76. PubMed ID: 23000694 [TBL] [Abstract][Full Text] [Related]
4. [Development of an efficient short interference RNA (siRNA) delivery system with a new pH-sensitive cationic lipid]. Sato Y; Hatakeyama H; Hyodo M; Akita H; Harashima H Yakugaku Zasshi; 2012; 132(12):1355-63. PubMed ID: 23208041 [TBL] [Abstract][Full Text] [Related]
5. Endosomal escape and the knockdown efficiency of liposomal-siRNA by the fusogenic peptide shGALA. Sakurai Y; Hatakeyama H; Sato Y; Akita H; Takayama K; Kobayashi S; Futaki S; Harashima H Biomaterials; 2011 Aug; 32(24):5733-42. PubMed ID: 21605898 [TBL] [Abstract][Full Text] [Related]
6. Improvement of doxorubicin efficacy using liposomal anti-polo-like kinase 1 siRNA in human renal cell carcinomas. Sakurai Y; Hatakeyama H; Akita H; Harashima H Mol Pharm; 2014 Aug; 11(8):2713-9. PubMed ID: 24800640 [TBL] [Abstract][Full Text] [Related]
7. Efficient Packaging of Plasmid DNA Using a pH Sensitive Cationic Lipid for Delivery to Hepatocytes. Sakurai Y; Matsuda T; Hada T; Harashima H Biol Pharm Bull; 2015; 38(8):1185-91. PubMed ID: 26235581 [TBL] [Abstract][Full Text] [Related]
8. Size-dependent specific targeting and efficient gene silencing in peritoneal macrophages using a pH-sensitive cationic liposomal siRNA carrier. Matsui H; Sato Y; Hatakeyama H; Akita H; Harashima H Int J Pharm; 2015 Nov; 495(1):171-178. PubMed ID: 26355712 [TBL] [Abstract][Full Text] [Related]
9. Efficient siRNA Delivery by Lipid Nanoparticles Modified with a Nonstandard Macrocyclic Peptide for EpCAM-Targeting. Sakurai Y; Mizumura W; Murata M; Hada T; Yamamoto S; Ito K; Iwasaki K; Katoh T; Goto Y; Takagi A; Kohara M; Suga H; Harashima H Mol Pharm; 2017 Oct; 14(10):3290-3298. PubMed ID: 28789523 [TBL] [Abstract][Full Text] [Related]
10. Novel pH-sensitive multifunctional envelope-type nanodevice for siRNA-based treatments for chronic HBV infection. Yamamoto N; Sato Y; Munakata T; Kakuni M; Tateno C; Sanada T; Hirata Y; Murakami S; Tanaka Y; Chayama K; Hatakeyama H; Hyodo M; Harashima H; Kohara M J Hepatol; 2016 Mar; 64(3):547-55. PubMed ID: 26505121 [TBL] [Abstract][Full Text] [Related]
11. Systemic delivery of siRNA to tumors using a lipid nanoparticle containing a tumor-specific cleavable PEG-lipid. Hatakeyama H; Akita H; Ito E; Hayashi Y; Oishi M; Nagasaki Y; Danev R; Nagayama K; Kaji N; Kikuchi H; Baba Y; Harashima H Biomaterials; 2011 Jun; 32(18):4306-16. PubMed ID: 21429576 [TBL] [Abstract][Full Text] [Related]
12. Novel antiangiogenic therapy targeting biglycan using tumor endothelial cell-specific liposomal siRNA delivery system. Maishi N; Sakurai Y; Hatakeyama H; Umeyama Y; Nakamura T; Endo R; Alam MT; Li C; Annan DA; Kikuchi H; Morimoto H; Morimoto M; Akiyama K; Ohga N; Hida Y; Harashima H; Hida K Cancer Sci; 2022 May; 113(5):1855-1867. PubMed ID: 35266253 [TBL] [Abstract][Full Text] [Related]
13. A pH-sensitive fusogenic peptide facilitates endosomal escape and greatly enhances the gene silencing of siRNA-containing nanoparticles in vitro and in vivo. Hatakeyama H; Ito E; Akita H; Oishi M; Nagasaki Y; Futaki S; Harashima H J Control Release; 2009 Oct; 139(2):127-32. PubMed ID: 19540888 [TBL] [Abstract][Full Text] [Related]
14. Efficient short interference RNA delivery to tumor cells using a combination of octaarginine, GALA and tumor-specific, cleavable polyethylene glycol system. Sakurai Y; Hatakeyama H; Akita H; Oishi M; Nagasaki Y; Futaki S; Harashima H Biol Pharm Bull; 2009 May; 32(5):928-32. PubMed ID: 19420766 [TBL] [Abstract][Full Text] [Related]
15. A Multifunctional Envelope-Type Nano Device Containing a pH-Sensitive Cationic Lipid for Efficient Delivery of Short Interfering RNA to Hepatocytes In Vivo. Sato Y; Harashima H; Kohara M Methods Mol Biol; 2016; 1364():71-8. PubMed ID: 26472443 [TBL] [Abstract][Full Text] [Related]
16. Failure of active targeting by a cholesterol-anchored ligand and improvement by altering the lipid composition to prevent ligand desorption. Yamamoto S; Sakurai Y; Harashima H Int J Pharm; 2018 Jan; 536(1):42-49. PubMed ID: 29126905 [TBL] [Abstract][Full Text] [Related]
17. Small interfering RNA delivery into the liver by cationic cholesterol derivative-based liposomes. Hattori Y; Machida Y; Honda M; Takeuchi N; Yoshiike Y; Ohno H; Onishi H J Liposome Res; 2017 Dec; 27(4):264-273. PubMed ID: 27345333 [TBL] [Abstract][Full Text] [Related]
18. siRNA delivery by a transferrin-associated lipid-based vector: a non-viral strategy to mediate gene silencing. Cardoso AL; Simões S; de Almeida LP; Pelisek J; Culmsee C; Wagner E; Pedroso de Lima MC J Gene Med; 2007 Mar; 9(3):170-83. PubMed ID: 17351968 [TBL] [Abstract][Full Text] [Related]
19. Reducing the Cytotoxicity of Lipid Nanoparticles Associated with a Fusogenic Cationic Lipid in a Natural Killer Cell Line by Introducing a Polycation-Based siRNA Core. Nakamura T; Yamada K; Fujiwara Y; Sato Y; Harashima H Mol Pharm; 2018 Jun; 15(6):2142-2150. PubMed ID: 29668291 [TBL] [Abstract][Full Text] [Related]
20. Improved Stability of siRNA-Loaded Lipid Nanoparticles Prepared with a PEG-Monoacyl Fatty Acid Facilitates Ligand-Mediated siRNA Delivery. Sakurai Y; Mizumura W; Ito K; Iwasaki K; Katoh T; Goto Y; Suga H; Harashima H Mol Pharm; 2020 Apr; 17(4):1397-1404. PubMed ID: 32091909 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]